Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Colorectal Neoplasms 3Brain Neoplasms 3Rectal Neoplasms 2Pain, Postoperative 2Neurotoxicity Syndromes 2Neoplasms 2Mesothelioma 2Colonic Neoplasms 2Agnosia 2Urinary Bladder Neoplasms 1Upper Abdominal Cancer Surgery 1Thyroid Neoplasms 1Supratentorial Brain Tumor 1Stomach Neoplasms 1Seizures 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Primary Immunodeficiency Diseases 1Pain 1Paclitaxel-induced Neuropathy 1Myoma 1Leukemia, Myeloid, Acute 1Infections 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Colorectal Cancer Screening 1Anesthesia 1

Interventions

AP 1903 reagent 3threonic acid 1fludarabine phosphate 1fludarabine 1Thiotepa 1Tacrolimus 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Melphalan 1Magnesium Sulfate 1Cyclophosphamide 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Primary Immunodeficiency Diseases × Magnesium Sulfate × Clear all
NCT02496676 2022-03-02

Magnesium Supplementation in People With XMEN Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 7 charts

Primary Immunodeficiency Diseases, Infections, Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡